BOLT | tickerfilter.com

Fundamental analysis

10%

Profitability 0%

Dept financing 7%

Liquidity 75%

Performance 6%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.45%

1 Month

-7.19%

3 Months

-10.74%

6 Months

-43.06%

1 Year

-40.04%

2 Year

-61.50%

Key data

Stock price

$0.69

P/E Ratio

-0.39

DAY RANGE

N/A - N/A

EPS

-$1.74

52 WEEK RANGE

$0.65 - $1.56

52 WEEK CHANGE

-$0.37

MARKET CAP

25.928 M

YIELD

N/A

SHARES OUTSTANDING

38.265 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

0.70

PUBLIC FLOAT

AVERAGE 10 VOLUME

$107,019

AVERAGE 30 VOLUME

$226,783

Company detail

CEO:
Region: US
Website: https://boltbio.com/
Employees: 92
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

bolt biotherapeutics is a start-up with compelling technology from dr. engleman’s lab at stanford university, which demonstrated complete cures in numerous cancer models. the company is backed by strong life sciences investors and is early in its growth curve, seeking bright, highly motivated individuals that will be the company’s future leaders to help it further develop and bring to patients novel and curative biotherapies.

BOLT - Bolt Biotherapeutics Inc